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Abstract
Background
Left ventricular hypertrophy (LVH) and myocardial contractile dysfunction are independent
predictors of mortality in patients with chronic kidney disease (CKD). The association be-
tween inflammatory biomarkers and cardiac geometry has not yet been studied in a large
cohort of CKD patients with a wide range of kidney function.
Methods
Plasma levels of interleukin (IL)-1β, IL-1 receptor antagonist (IL-1RA), IL-6, tumor necrosis
factor (TNF)-α, transforming growth factor (TGF)-β, high-sensitivity C-Reactive protein (hs-
CRP), fibrinogen and serum albumin were measured in 3,939 Chronic Renal Insufficiency
Cohort study participants. Echocardiography was performed according to the recommenda-
tions of the American Society of Echocardiography and interpreted at a centralized core
laboratory.
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Results
LVH, systolic dysfunction and diastolic dysfunction were present in 52.3%, 11.8% and
76.3% of the study subjects, respectively. In logistic regression analysis adjusted for age,
sex, race/ethnicity, diabetic status, current smoking status, systolic blood pressure, urinary
albumin- creatinine ratio and estimated glomerular filtration rate, hs-CRP (OR 1.26 [95% CI
1.16, 1.37], p<0.001), IL-1RA (1.23 [1.13, 1.34], p<0.0001), IL-6 (1.25 [1.14, 1.36], p<0.001)
and TNF-α (1.14 [1.04, 1.25], p = 0.004) were associated with LVH. The odds for systolic
dysfunction were greater for subjects with elevated levels of hs-CRP (1.32 [1.18, 1.48],
p<0.001) and IL-6 (1.34 [1.21, 1.49], p<0.001). Only hs-CRP was associated with diastolic
dysfunction (1.14 [1.04, 1.26], p = 0.005).
Conclusion
In patients with CKD, elevated plasma levels of hs-CRP and IL-6 are associated with LVH
and systolic dysfunction.
Introduction
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular (CV) mortality and
morbidity in the general population as well as in patients with chronic kidney disease (CKD).
[1,2] Although LVH begins as an adaptive response to pressure or volume overload, it often re-
sults in diastolic dysfunction, eventually leading to heart failure. Abnormal cardiac geometry in
patients with CKD has been attributed to a number of established risk factors as well as risk fac-
tors unique to CKD.[3,4] Evidence from experimental studies indicates that cytokines regulate
cardiac remodeling and contractile function.[5,6] However, to date, no large scale study has ex-
amined the association between biomarkers of inflammation and cardiac geometry in a multi-
racial cohort of subjects with established CKD. Understanding the role of inflammatory
molecules in the pathogenesis of heart disease in CKD is important for the design and imple-
mentation of targeted anti-inflammatory therapies.
We recently reported that biomarkers of inflammation were inversely associated with mea-
sures of kidney function and positively with the magnitude of proteinuria in chronic renal in-
sufficiency cohort (CRIC) study participants.[7] In the same cohort, Park et al [8] found that
the risk of LVH was increased among subjects with a cystatin based estimated glomerular filtra-
tion rate (eGFR) of less than 30 ml/min per 1.73 m2. In the present study, we examined wheth-
er systemic inflammation is a predictor of cardiac structure and function independent of the
level of kidney function.
Materials and Methods
The CRIC study is an ongoing, multicenter, prospective observational cohort study of men and
women with CKD. The design of the CRIC study has been previously reported.[9] All of the
3,939 study participants have provided written informed consent. The study complies with the
Declaration of Helsinki and the protocol was approved by the Institutional Review Board at
each participating site (University of Pennsylvania, Philadelphia, PA; Johns Hopkins Medicine,
Baltimore, MD; University of Maryland, College Park, MD; University Hospitals Case Medical
Center, Cleveland, OH; MetroHealth System, Cleveland, OH; Cleveland Clinic Foundation,
Cleveland, OH; University of Michigan, Ann Arbor, MI; St. John Hospital and Medical Center,
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CRIC data collection
Demographic characteristics, medical history, smoking status, weight, height, body mass index
(BMI) and use of medications including statins, angiotensin converting enzyme inhibitors
(ACEI) and angiotensin receptor blockers (ARB) were recorded at baseline. Serum creatinine
was measured by the Jaffe method on a Beckman Synchron System. eGFR was computed using
the Modification of Diet in Renal Disease estimating equation.[10] Proteinuria was measured
as the ratio of albumin to creatinine in the urine (UACR).
Measurement of biomarkers of inflammation
Biomarker measurements were performed as described earlier.[7] Briefly, high sensitivity sand-
wich ELISAs (Quantikine HS, R&D Systems, Minneapolis, MN) were used to measure plasma
interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α levels. Standard sandwich ELISAs
(Quantikine, R&D Systems) were used to quantify IL-1 receptor antagonist (IL-1RA) and
transforming growth factor (TGF)-β levels. Integrated performance of IL-1β, IL-1RA, IL-6, and
TNF-α ELISAs were implemented using a robotic liquid handling platform (Biomek FXp,
Beckman Coulter, Brea, CA). All cytokine assays were performed in duplicates and mean val-
ues used in the analysis. High sensitivity C-reactive protein (hs-CRP) and fibrinogen were
quantified in EDTA plasma samples using specific laser-based immunonephelometric methods
on the BNII (Siemens Healthcare Diagnostics, Deerfield, IL).
Echocardiography
Echocardiography was performed on all study participants within 14 months of enrollment in
the study. Studies were performed according to the recommendations of the American Society
of Echocardiography and interpreted at a centralized, quality-controlled quantitative echocar-
diography core laboratory.[11] LV mass was calculated using the area–length method and in-
dexed to height2.7 (LVMI).[11,12] LVH was defined as LV mass/height2.7 47 g/m2.7 in
women and50 g/m2.7 in men.[13] Relative wall thickness (RWT) was calculated as 2 × posteri-
or wall thickness/LV internal linear dimension in diastole. Based on the LVMI and RWTmea-
surements,[11] four geometric patterns were described:
a. normal (normal LVMI and normal RWT)
b. concentric remodeling (normal LVMI and increased RWT)
c. eccentric hypertrophy (abnormally increased LVMI and normal RWT), and
d. concentric hypertrophy (abnormally increased LVMI and increased RWT).
Mitral inflow E- and A-wave velocities, E-wave deceleration time, and pulmonary venous
reverse A-wave duration were used to categorize LV diastolic function, using well-estab-
lished criteria.[14] LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV)
were calculated using the modified biplane method. Ejection fraction was calculated as
(LVEDV-LVESV)/LVEDV. Systolic dysfunction was defined as ejection fraction <45%.
[8,15]
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Statistical Analyses
Descriptive statistics for selected demographic and clinical characteristics of the study popula-
tion stratified by the presence of LVH are presented. Values are presented as frequency (per-
centage), mean (standard deviation; SD) and median (inter-quartile range; IQR) as
appropriate. Two sample t-test, Wilcoxon rank-sum test and Pearson’s chi-squared test were
used to compare continuous and categorical variables across the LVH strata. The association of
inflammatory biomarkers with the presence of LVH, systolic dysfunction and diastolic dys-
function were examined with logistic regression models. Multinomial logistic regression was
used to examine the association between inflammatory biomarkers and cardiac geometry (the
outcomes of concentric hypertrophy, concentric remodeling, and eccentric hypertrophy, with
normal cardiac geometry as reference). Linear regression models were used to investigate the
association of the inflammatory biomarkers with LVMI and ejection fraction. All models were
adjusted for age, sex, race/ethnicity, diabetic status, current smoking status, systolic blood pres-
sure, eGFR and log transformed UACR. The addition of ACEI-ARB use as a covariate did not
influence the effect estimates and p-values and therefore it was not included in the final models.
All principal predictors (hs-CRP, fibrinogen, serum albumin, IL-1β, IL-1RA, IL-6, TNF-α and
TGF-β) were log-transformed and expressed in standard deviation units for use in regression
analyses. Bonferroni’s correction was used to adjust for multiple comparisons. All analyses
were performed using the SAS statistical software (version 9.3; SAS Inc., Cary, NC).
Results
Demographic and clinical characteristics of the participants categorized by the presence of
LVH are shown in Table 1. LVH was present in 1,631 (52.3%) participants and 16.8% of those
with LVH had ejection fraction<45%. Those with LVH were more likely to be female, non-
Hispanic Black, older in age, former smoker, diabetic, hypertensive and with reduced kidney
function when compared to those without LVH. As a group, they also had a higher systolic BP
and a larger BMI, and were more likely to report ACEI-ARB use than the group without LVH.
Subjects with LVH also had lower levels of serum albumin and higher levels of inflammatory
biomarkers (except TGF-β) on an average compared to those without LVH.
In multivariable linear regression analyses, hs-CRP [regression coefficient = 1.50 (95% Con-
fidence intervals: 1.05, 1.96), p<0.001], IL-1β [0.76 (0.30, 1.23), p = 0.0010], IL-1RA [1.30
(0.84, 1.75), p<0.0001], IL-6 [1.53 (1.05, 2.01), p<0.001] and TNF-α [0.72 (0.23, 1.21),
p = 0.004] were associated with LVMI (Table 2). Serum albumin level was negatively associated
with LVMI [-1.24 (-1.76,-0.71), p<0.001]. hs-CRP [-0.75 (-1.05, -0.46), p<0.001] and IL-6
[-0.91 (-1.22, -0.60), p<0.001] were both negatively associated with ejection fraction.
LVH, systolic dysfunction and diastolic dysfunction were present in 1,631 (52.3%), 411
(11.8%) and 2,330 (76.3%) of the participants, respectively. (Table 3) Adjusted logistic regres-
sion analysis showed that hs-CRP [Odds Ratio = 1.26 (95% Confidence intervals: 1.16, 1.37),
p<0.001), IL-1RA [1.23 (1.13, 1.34), p<0.001], IL-6 [1.25 (1.14, 1.36), p<0.001], and TNF-α
[1.14 (1.04, 1.25), p = 0.004] were associated with the presence of LVH. The odds for having
systolic dysfunction were greater for higher levels of hs-CRP [1.32 (1.18, 1.48), p<0.001] and
IL-6 [1.34 (1.21, 1.49), p<0.001]. Only hs-CRP [1.14 (1.04, 1.26), p = 0.005] was associated
with the presence of diastolic dysfunction.
Concentric remodeling, concentric hypertrophy and eccentric hypertrophy were present in
855 (28.6%), 1,102 (36.9%) and 447 (15.0%) participants, respectively. (Table 4) When inflam-
matory markers were examined for their associations with cardiac geometry using an adjusted
multinomial logistic regression model, hs-CRP [Odds Ratio = 1.32 (95% Confidence Intervals:
1.17, 1.49), p<0.001], IL-1β [1.24 (1.1, 1.4), p<0.001], IL-1RA [1.4 (1.24, 1.58), p<0.001] and
Inflammation and LVH
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IL-6 [1.29 (1.13, 1.47), p<0.001] were each associated with concentric hypertrophy. Only
TGF-β was associated with a higher risk of concentric remodeling [1.21 (1.09, 1.35), p<0.001].
Eccentric hypertrophy was positively associated with hs-CRP ([1.38 (1.20, 1.58), p<0.001], IL-
1RA [1.24 (1.08, 1.43), p = 0.002] and IL-6 [1.31 (1.13, 1.52), p<0.001], but negatively associat-
ed with serum albumin level [0.78 (0.67, 0.91), p = 0.002].
Discussion
A number of investigators have reported an association between inflammation and increased
CV mortality in CKD.[16,17] In this study, we examined the association of circulating bio-
markers of inflammation with echocardiographically determined cardiac structure and func-
tion using CRIC study participants and found significant associations between several
inflammatory biomarkers and LVH and systolic dysfunction after adjusting for several tradi-
tional CV risk factors as well as measures of kidney function. Of all biomarkers, hs-CRP and
IL-6 were more consistently associated with abnormal cardiac geometry and contractile dys-
function. Lower serum albumin was associated with LVMI and eccentric hypertrophy. Thus,
Table 1. Baseline demographic and clinical characteristics of the study cohort categorized by the presence of LVH.
Variables presented as n (%), mean ± standard deviation and median (interquartile range)
as appropriate
LVH absent
n = 1488
LVH present
n = 1631
p-
value
Females 647 (43.5) 785 (48.1) 0.009
Race/ethnicity <0.001
Non-Hispanic white 796 (53.5) 499 (30.6)
Non-Hispanic Black 512 (34.4) 790 (48.4)
Hispanic 117 (7.9) 281 (17.2)
Other 63 (4.2) 61 (3.7)
Diabetes 524 (35.2) 956 (58.6) <0.001
Hypertension 1153 (77.5) 1522 (93.3) <0.001
Ever smoked 753 (50.6) 907 (55.6) 0.005
Smoke now 174 (11.7) 206 (12.6) 0.42
ACEI-ARB use 957 (64.6) 1169 (72.2) <0.001
Age (years) 55.7 ± 11.6 59 ± 10.2 <0.001
Systolic BP (mmHg) 121.7 ± 18.8 134 ± 22.5 <0.001
Diastolic BP (mmHg) 71.2 ± 11.8 72.1 ± 13.5 0.07
BMI (kg/m2) 28.8 ± 5.8 34 ± 7.5 <0.001
eGFR (ml/min/1.73m2 46.1±13.5 40.2 (13) <0.001
UACR (mcg/mg) 21.1 (5.9, 203.8) 109.2 (14.7, 868.2) <0.001
Total cholesterol (mmol/L) 4.8 ± 1.11 4.7± 1.2 0.09
Hemoglobin (g/L 130 ± 17.0 122 ±18.0 <0.001
hs-CRP (nmol/L) 18.1 (8.6, 44.8) 27.6 (11.4, 66.7) <0.001
Fibrinogen (μmol/L) 11.2 (9.4, 12.9) 12.6 (10.6, 14.7) <0.001
Albumin (g/L) 41.0 (38.1, 43.0) 39.0 (36.0, 42.0) <0.001
IL-1β (pg/ml) 0 (0, 0.9) 0.3 (0, 1.5) <0.001
IL-1RA (pg/ml) 599.7 (328.0,
1298.5)
809.2 (424.7,
1646.7)
<0.001
IL-6 (pg/ml) 1.4 (0.9, 2.4) 2.1 (1.4, 3.3) <0.001
TNF-α (pg/ml) 1.9 (1.3, 2.8) 2.4 (1.7, 3.4) <0.001
TGF-β (pg/ml) 10.7 (6.2, 18.1) 10.8 (6.5, 17.6) 0.7
LVH was defined as LV mass/height2.7 47 g/m2.7 in women and 50 g/m2.7 in men.UACR = Urine albumin to creatinine ratio
doi:10.1371/journal.pone.0124772.t001
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this study shows that inflammation is a potential modulator of cardiac remodeling and func-
tion in patients with CKD.
Laboratory-based studies have shown that cytokines promote cardiac remodeling by stimu-
lating sarcomeric protein synthesis, enhancing fetal gene expression, altering extracellular ma-
trix degradation and triggering apoptosis.[6,18,19] Although most of the circulating cytokines
are secreted from activated macrophages and lymphocytes, adipocytes and skeletal muscle are
also possible sources of these biomolecules.[20,21] Proinflammatory cytokines are not consti-
tutively expressed in the myocardium, but are upregulated in response to myocardial injury
and may contribute to circulating levels.[22] CRP is a predictor of CVD in the general popula-
tion and in patients with CKD.[23,24] In a cohort of resistant hypertensive patients. microalbu-
minuria and high CRP were independently associated with the occurrence of LVH.[25] In a
Table 2. Adjusted linear regression models showing the association of inflammatory biomarkers with LVMI and ejection fraction.
Predictor Outcome
LVMI; n = 3,119 Ejection Fraction %; n = 3,484
Regression coefficient (95% CI) p-value Regression coefficient (95% CI) p-value
hs-CRP 1.5 (1.05, 1.96) <0.001* -0.75 (-1.05, -0.46) <0.001*
Fibrinogen 0.2 (-0.27, 0.67) 0.41 -0.2 (-0.51, 0.10) 0.19
Albumin -1.24 (-1.76,-0.71) <0.001* 0.03 (-0.31, 0.37) 0.84
IL-1β 0.76 (0.30, 1.23) 0.001* -0.25 (-0.55, 0.05) 0.11
IL-1RA 1.3 (0.84, 1.75) <0.001* -0.18 (-0.47, 0.12) 0.24
IL-6 1.53 (1.05, 2.01) <0.001* -0.91 (-1.22, -0.60) <0.001*
TNF-α 0.72 (0.23, 1.21) 0.004* -0.12 (-0.44, 0.19) 0.44
TGF-β -0.38 (-0.83, 0.07) 0.1 0.04 (-0.25, 0.33) 0.77
Left ventricular mass index (LVMI) was calculated using the area–length method and indexed to height2.7
* Significant after Bonferroni correction for multiple comparisons (corrected p-value: 0.05/8 = 0.006).
doi:10.1371/journal.pone.0124772.t002
Table 3. Adjusted logistic regression models showing the association of inflammatory biomarkers with LVH, systolic dysfunction and diastolic
dysfunction.
Predictor Outcome
Left ventricular hypertrophy;
n = 3,119
Systolic dysfunction; n = 3,484 Diastolic dysfunction; n = 3,053
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
hs-CRP 1.26 (1.16, 1.37) <0.001* 1.32 (1.18, 1.48) <0.001* 1.14 (1.04, 1.26) 0.005*
Fibrinogen 1.07 (0.98, 1.17) 0.14 1.02 (0.91, 1.15) 0.76 1.12 (1.02, 1.23) 0.01
Albumin 0.88 (0.80, 0.97) 0.009 0.97 (0.86 1.09) 0.57 1 (0.9, 1.11) 0.94
IL-1β 1.11 (1.03 1.21) 0.01 1.04 (0.93, 1.17) 0.47 1.04 (0.95, 1.15) 0.39
IL-1RA 1.23 (1.13, 1.34) <0.001* 1.04 (0.94 1.16) 0.45 1.1 (1, 1.21) 0.05
IL-6 1.25 (1.14, 1.36) <0.001* 1.34 (1.21, 1.49) <0.001* 1.06 (0.95, 1.17) 0.3
TNF-α 1.14 (1.04, 1.25) 0.004* 1.09 (0.97, 1.23) 0.14 1.12 (1.01, 1.24) 0.03
TGF-β 0.92 (0.85, 1.00) 0.05 1.07 (0.96, 1.19) 0.24 1.01 (0.92, 1.11) 0.78
LVH was defined as LV mass/height2.7 47 g/m2.7 in women and 50 g/m2.7 in men
Systolic dysfunction was defined as ejection fraction <45%
* Significant after Bonferroni correction for multiple comparisons (corrected p-value: 0.05/8 = 0.006).
doi:10.1371/journal.pone.0124772.t003
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small study, involving 104 maintenance hemodialysis patients, hs-CRP and systolic BP were in-
dependent predictors of LVH. [26] Whether CRP is just a marker of overall inflammatory state
or a direct mediator of LVH is currently uncertain.
Based on LVMI and RWT, four patterns of cardiac geometry were recognized. Abnormal
cardiac geometry is associated with CV events in patients with CKD.[27,28] In the current
study, the presence of both concentric and eccentric hypertrophy was associated with elevated
levels of hs-CRP and inflammatory cytokines. Circulating IL-6 was associated with the pres-
ence of both concentric and eccentric hypertrophy. In two hypertensive rat models, Kurdi et al.
showed that IL-6 and leukemia inhibitory factor contributed to angiotensin II-dependent
LVH. [29] In vitro studies show that IL-6 mediates cardiac myocyte hypertrophy by an auto-
crine pathway and fibroblast proliferation by a paracrine pathway.[5,30] In the current study,
low serum albumin was associated with LVMI as well as with the presence of eccentric hyper-
trophy. A strong association between serum albumin and LV dilation has been reported in
end-stage renal disease patients.[31] The link between serum albumin and cardiac geometry
could be a reflection of underlying inflammation as well as other associated comorbidities such
as protein energy wasting.
Heart failure may be due to systolic or diastolic dysfunction, or both.[32] In the present
study, ejection fraction was negatively associated with hs-CRP and IL-6. The contractile func-
tion of isolated cardiac myocytes is modulated by cytokines through activation of the neutral
sphingomyelinase pathway and by NO-mediated blunting of β-adrenergic signaling.[33,34]
Pro-inflammatory cytokines may also promote diastolic heart failure through down-regulation
of diastolic calcium reuptake by sarcoplasmic reticulum.[35] However, in our study only hs-
CRP was associated with an increased risk for diastolic dysfunction.
The cross-sectional associations reported in this study should be interpreted with caution.
Cytokines are pleiotropic in their actions, and exhibit interactive cascades in which they induce
or repress their own synthesis as well as that of other cytokines and cytokine receptors.[36] An
important component of the inflammatory cascade is the acute-phase response, which is regu-
lated by cytokines such as IL-6. Zoccali et al.[37] showed that an inflammation score based on
CRP, IL-6, IL-1β, IL-18 and TNF-α was not superior to IL-6 in predicting mortality in patients
with ESRD. In the present study as well, IL-6 emerged as a strong and independent predictor of
unfavorable cardiac geometry.
Table 4. Adjustedmultinomial logistic regression models showing the association of inflammatory biomarkers with cardiac geometry.
Predictor Outcome
Concentric hypertrophy; n = 1,102 Concentric remodeling; n = 855 Eccentric hypertrophy; n = 447
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
hs-CRP 1.32 (1.17, 1.49) <0.001* 1.10 (0.98, 1.24) 0.1 1.38 (1.20, 1.58) <0.001*
Fibrinogen 1.02 (0.91, 1.15) 0.76 1.00 (0.90, 1.12) 0.95 1.2 (1.01, 1.43) 0.03
Albumin 0.93 (0.81, 1.07) 0.29 0.99 (0.86, 1.13) 0.85 0.78 (0.67, 0.91) 0.002*
IL-1β 1.24 (1.1, 1.4) <0.001* 1.08 (0.97, 1.22) 0.17 1.09 (0.95, 1.25) 0.23
IL-1RA 1.40 (1.24, 1.58) <0.001* 1.15 (1.02, 1.29) 0.02 1.24 (1.08, 1.43) 0.002*
IL-6 1.29 (1.13, 1.47) <0.001* 1.08 (0.95, 1.23) 0.27 1.31 (1.13, 1.52) <0.001*
TNF-α 1.14 (1.01, 1.3) 0.04 0.96 (0.85, 1.09) 0.53 1.07 (0.92, 1.24) 0.4
TGF-β 1.05 (0.93, 1.17) 0.45 1.21 (1.09, 1.35) <0.001* 1.01 (0.88, 1.15) 0.93
* Significant after Bonferroni correction for multiple comparisons (corrected p-value: 0.05/8 = 0.006).
doi:10.1371/journal.pone.0124772.t004
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A number of studies have demonstrated that single measures of various inflammatory bio-
markers at baseline are important determinants of subsequent adverse outcomes in subjects
with kidney disease.[37,38] In a study involving 62 subjects without kidney disease, single mea-
sures of hs-CRP, TNF-α, IL-8, and soluble TNF receptor I and II accurately reflected the in-
flammatory status over a 4–6-month period.[39] However, intra-individual variation in
inflammatory biomarkers is also reported in subjects with and without kidney disease.[40–42]
In the Mapping of Inflammatory Markers in Chronic Kidney Disease (MIMICK) Study, in-
flammatory markers were measured over 3 months in 228 hemodialysis patients. Baseline CRP
level was highly correlated with time-averaged CRP as well as with the median of serial CRP
values.[43] However, in the multivariate Cox model, median CRP level was associated more
strongly with mortality than a single baseline value, indicating that serial CRP values over time
is superior in estimation of the patient's risk profile.[43]
Our study has a number of strengths which include: (a) a large cohort of patients from dif-
ferent races/ethnicities with a broad range of kidney function; (b) examination of a large panel
of biomarkers with pro- and anti-inflammatory properties; and (c) consideration of traditional
CV risk factors. Echocardiography performed using a standardized protocol, which included
quality control of the measurements, is an added strength. However, these findings should be
considered within the context of some limitations: (a) this is a cross-sectional analysis and
hence temporal associations and causality cannot be inferred; (b) biomarkers were measured at
one time point only; and (c) some echocardiographic parameters were not available in a subset
of study participants due to technical difficulties.
Conclusions
To summarize, using a large cohort of well characterized CKD subjects, this study demon-
strates that abnormal cardiac structure and function are associated with specific biomarkers of
inflammation. Specifically, elevated hs-CRP and IL-6 were independently and consistently as-
sociated with LVH and systolic dysfunction. Low serum albumin was associated with higher
LVMI and eccentric hypertrophy. Among the pro-inflammatory biomarkers studied, IL-6 ap-
pears to best capture the inflammatory status as well as the association with adverse cardiac re-
modeling in CKD patients. The prognostic implications and the utility of IL-6 as a therapeutic
target warrant further investigation.
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